Role of 5-HT in stress, anxiety, and depression

Pharmacology Biochemistry and Behavior

Volumn 54, Issue 1, 1996, Pages 129-141

  Graeff, Frederico G ^a   Guimarães, Francisco S ^a   De Andrade, Telma G C S ^b   Deakin, John F W ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5 HT; anxiety; conditioned skin conductance responses; depression; dorsal hippocampus; dorsal raphe nucleus; elevated plus maze; elevated T maze; median raphe nucleus; restraint stress; simulated public speaking; stress

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 METHOXY N,N DIMETHYLTRYPTAMINE; BENZODIAZEPINE RECEPTOR INVERSE STIMULATING AGENT; DEXFENFLURAMINE; DIAZEPAM; EPLIVANSERIN; EXCITATORY AMINO ACID; FG 4172; IPSAPIRONE; KAINIC ACID; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; RITANSERIN; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; ZIMELDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; AVOIDANCE BEHAVIOR; BRAIN INJURY; CONDITIONING; CONFERENCE PAPER; DEPRESSION; DORSAL RAPHE NUCLEUS; FEAR; HIPPOCAMPUS; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MAZE TEST; MEDIAN RAPHE NUCLEUS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SKIN CONDUCTANCE; STOMACH ULCER; STRESS; VOLUNTEER;

EID: 0342398240     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02135-3     Document Type: Conference Paper

References (112)

1. Aghajanian, G. K. Central 5-HT receptor subtypes: Physiological responses and signal transduction mechanisms. In: Marsden, C. A.; Heal, D. J., eds. Central serotonin receptors and psychoptropic drugs. Oxford: Blackwell Scientific Publications; 1992: 39-55.
2. Anisman, H.; Zalcman, S.; Zacharko, M. The impact of stressors on immune and central neurotransmitter activity: Bidirectional communication. Rev. Neurosci. 4:147-180; 1993.
3. Artigas, F. 5-HT and antidepressants: New views from microdialysis studies. Trends Pharmacol. Sci. 14:262; 1993.
4. Azmitia, E. C. The serotonin-producing neurons of the midbrain median and dorsal raphe nuclei. In: Iversen, L. L.; Iversen, S. D.; Snyder, S. H., eds. Handbook of psychopharmacology. Vol. 9: Chemical pathways in the brain. New York: Plenum Press; 1978:233-314.
5. 1A receptors. Br. J. Pharmacol. 100:793-799; 1990.
6. Baum, A.; Cohen, L.; Hall, N. M. Control of intrusive memories as possible determinants of chronic stress. Psychosom. Med. 55:274-286; 1993.
7. Bickerdike, M. J.; Wright, I. K.; Marsden, C. A. Social isolation attenuates rat forebrain 5-HT release induced by KCl stimulation and exposure to novel environment. Behav. Pharmacol. 4:231-236; 1993.
8. Blanchard, R. J.; Blanchard, D. C.; Hori, K. Ethoexperimental approaches to the study of defensive behavior. In: Blanchard, R. J.; Brain, P. F.; Blanchard, D.C.; Parmigiani, S., eds. Ethoexperimental approaches to the study of behavior. Dordrecht: Kluwer Academic Publishers; 1989:114-136.
9. Blier, P.; de Montigny, C.; Chaput, Y. Modification of the serotonin system by the antidepressant treatments: Implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7:24S-35S; 1987.
10. Bonvento, G.; Scatton, B.; Claustre, Y.; Rouquier, L. Effects of local injection of 8-OH-DPAT into the dorsal or median raphe nuclei on extracellular levels of serotonin in serotonergic projection areas in the rat brain. Neurosci. Lett. 132:101-104; 1992.
11. Briley, M.; Moret, C. Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol. 5:387-400; 1993.
12. 1A receptors. Br. J. Pharmacol. 105:720-726; 1992.
13. 1A agonist, impairs performance in a passive avoidance task. Eur. J. Pharmacol. 211:227-234; 1992.
14. 1A receptors in the dorsal hippocampus impairs acquisition and performance of a spatial task in a water maze. Brain Res. 595:50-56; 1992.
15. 1A receptor mRNA expression. J. Neurosci. 13:914-923; 1993.
16. 1A receptor gene expression by dexamethasone. Neuropsychopharmacology 10:215-222; 1994.
17. 1 binding sites in depressed suicides. Psychopharmacology (Berlin) 102:544-548; 1990.
18. 2 receptors and anxiety. Behav. Pharmacol. 6(Suppl. 1):35; 1995.
19. 2 receptors. Neuroscience 40:169-174; 1991.
20. Coppen, A. The biochemistry of affective disorders. Br. J. Psychiatry 113:1237-1264; 1967.
21. Corradetti, R.; Ballerini, L; Pugliesi, A. M.; Pepei, G. Serotonin blocks the long-term potentiation induced by primed burst stimulation in the CA1 region of the rat hippocamppal slices. Neuroscience 46:511-518; 1992.
22. De Montigny, C.; Blier, P. Effects of antidepressant treatment on 5-HT neurotransmission. In: Marsden, C. A.; Heal, D. J., eds. Central serotonin receptors and psychotropic drugs. Oxford: Blackwell Scientific Publications; 1992:223-238.
23. Deakin, J. W. F.; Graeff, F. G. 5-HT and mechanisms of defence. J. Psychopharmacol. 5:305-315; 1991.
24. Deakin, J. F. W.; Graeff, F. G.; Guimarães, F. S. 5-HT receptor subtypes and the modulation of aversion. In: Marsden, C. A.; Heal, D. J., eds. Central serotonin receptors and psychotropic drugs. Oxford: Blackwell Scientific Publications; 1992:147-174.
25. Deakin, J. F. W.; Guimarães, F. S.; Graeff, F. G. Testing theories of anxiety in normal volunteers. In: Palomo, T.; Archer, T., eds. Strategies for studying brain disorders. Vol. 1. Depressive, anxiety and drug abuse disorders. Madrid: Editorial Complutense; 1994:211-238.
26. Deakin, J. F. W.; Pennel, I.; Upadhyaya, A. K.; Lofthouse, R. A neuroendocrine study of 5-HT function in depression: Evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology (Berlin) 101:85-92; 1990.
27. Deakin, J. F. W.; Guimarães, F. S.; Wang, M.; Hellelwell, J.; Hensman, R. 5-HT receptor mechanisms in human anxiety. In: Briley, M.; File, S. E., eds. New concepts in anxiety. London: The Macmillan Press Ltd.; 1991:74-93.
28. Delgado, P. L.; Charney, D. S.; Price, L. H.; Aghajanian, G. K.; Landis, H.; Heninger, G. R. Serotonin function and the mechanism of antidepressant action. Arch. Gen. Psychiatry 47: 411-418; 1990.
29. Den Boer, J. A.; Westenberg, H. G. M. Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berlin) 102: 85-94; 1990.
30. Dickinson, S. L.; Kennett, G. A.; Curzon, G. Reduced 5-hydroxytryptamine dependent behaviour in rats following chronic corticosterone treatment. Brain Res. 345:10-18; 1985.
31. Dinan, T. G. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br. J. Psychiatry 164:365-371; 1994.
32. Dourish, C. T.; Gorka, Z.; Williams, A. R.; Iversen, S. D. Potential influence of social support in a rodent model of depression. J. Psychopharmacol. 3:38P; 1989.
33. Gower, A. J. 5-HT receptors and cognitive functions. In: Marsden, C. A.; Heal, D. J., eds. Central serotonin receptors and psychotropic drugs. Oxford: Blackwell Scientific Publications; 1992:239-259.
34. Graeff, F. G. Brain defense systems and anxiety. In: Roth, M.; Burrows, G. D.; Noyes, R., eds. Handbook of anxiety. Vol. 3: The neurobiology of anxiety. Amsterdam: Elsevier Science Publishers; 1990:307-354.
35. Graeff, F. G. Neurotransmitters in the dorsal periaqueductal gray and animal models of panic anxiety. In: Briley, M.; File, S. E., eds. New concepts in anxiety. London: Macmillan Press; 1991:288-312.
36. Graeff, F. G. Role of 5-HT in defensive behavior and anxiety. Rev. Neurosci. 4:181-211; 1993.
37. Graeff, F. G.; Viana, M. B.; Mora, P. O. Opposed regulation of dorsal raphe nucleus 5-HT pathways of two types of fear in the elevated T-maze. Pharmacol. Biochem. Behav. (in press).
38. Graeff, F. G.; Viana, M. B.; Mora, P. O. Dual role of 5-HT in defense and anxiety. Neurosci. Biobehav. Rev. (in press).
39. Graeff, F. G.; Viana, M. B.; Tomaz; C. The elevated T-maze, a new experimental model of anxiety and memory: Effect of diazepam. Braz. J. Med. Biol. Res. 26:67-70; 1993.
40. Graeff, F. G.; Silveira, M. C. L.; Nogueira, R. L.; Audi, E. A.; de Oliveira, R. M. W. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav. Brain Res. 58:123-131; 1993.
41. Guimarães, F. S.; Del Bel, E. A.; Padovan, C. M.; Mendonça Netto, S.; Titze de Almeida, R. Hippocampal 5-HT receptors and consolidation of stressful memories. Behav. Brain Res. 58: 133-139; 1993.
42. Guimarães, F. S.; Hellewell, J.; Hensman, R.; Wang, M.; Deakin, J. F. W. Characterization of a psychophysiological model of classical fear conditioning in healthy volunteers: Influence of gender, instructions, personality and placebo. Psychopharmacology (Berlin) 104:231-236; 1991.
43. Handley, S. L.; Mithani, S. Effects of alpha-adrenoceptor agonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn Schmiedebergs Arch. Pharmacol. 327:1-5; 1984.
44. Hensman, R.; Guimarães, F. S.; Wang, M.; Deakin, J. F. W. The effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology (Berlin) 104:220-224; 1991.
45. Hetem, L. A. B.; De Souza, C. J.; Guimarães, F. S. G.; Zuardi, A. W; Graeff, F. G. D-Fenfluramine reduces anxiety induced by simulated public speaking. Braz. J. Med. Biol. Res. 26:971-974; 1993.
46. 1A receptor agonists in two models of anxiety after dorsal raphe injection. Psychopharmacology (Berlin) 106:261-267; 1992.
47. Hodges, H.; Green, S.; Glenn, B. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not in discrimination. Psychopharmacology (Berlin) 92:491-504; 1987.
48. Hoshino, K.; Sugizaki, M. Ulcerogenic effect of the lesion of the median raphe nucleus in fasted rats. Braz. J. Med. Biol. Res. 19:123-130; 1986.
49. 3 antagonists and benzodiazepines. Chichester, UK: John Wiley & Sons; 1991:31-57.
50. Hoyer, D.; Palacios, J. M.; Mengod, G. 5-HT receptor distribution in human brain: Autoradiographic studies. In: Marsden, C. A.; Heal, D. J., eds. Central serotonin receptors and psychotropic drugs. Oxford: Blackewll Scientific Publications; 1992: 100-125.
51. 2 sites in cortex and amygdala. Brain Res. 614:37-44; 1993.
52. Humble, M.; Aberg-Wistedt, B. Bertilson, L. A pilot study of ritanserin (a selective serotonin-2 receptor antagonist) in panic disorder and agoraphobia. Clinical and biochemical effects. 5th CINP Congress, San Juan, Puerto Rico, Abstract P-165; 1986.
53. Iversen, S. D. 5-HT and anxiety. Neuropharmacology 23:1553-1560; 1984.
54. Joels, M.; Hesen, W.; de Kloet, E. R. Mineralocorticoid hormones suppress serotonin-induced hyperpolarization of rat hippocampus CA1 neurons. J. Neurosci. 11:2288-2294; 1991.
55. Jones, B. J.; Paterson, I. A.; Roberts, M. H. T. Microinjections of methyl-β-carboline-3-carboxylate into the dorsal raphe nucleus: Behavioural consequences. Pharmacol. Biochem. Behav. 24:1487-1489; 1986.
56. Kahn, R. S.; van Praag, H. M.; Wetzler, S.; Asnis, G. M.; Barr, G. Serotonin and anxiety revisited. Biol. Psychiatry 23:189-208; 1988.
57. Kálen, P.; Rosegren, E.; Lindvall, O.; Bjorklund, A. Hippocampal noradrenaline and serotonin release over 24 hours as measured by the dyalisis technique in freely moving rats: Correlation to behavioural activity state, effect of handling and tail pitch. Eur. J. Neurosci. 1:181-188; 1989.
58. Kendler, K. S.; Kessler, R. C.; Neale, M. C.; Heath, A. C.; Eaves, L. J. The prediction of major depression in women: Toward an integrated etiological model. Am. J. Psychiatry 150: 1139-1148; 1993.
59. 1C receptors and their therapeutic relevance. Curr. Opin. Invest. Drugs 2:317-362; 1993.
60. Kennett, G. A.; Dickinson, S. L.; Curzon, G. Central serotonergic responses and behavioral adaptation to repeated immobilisation: The effect of the corticosterone synthesis inhibitor metyrapone. Eur. J. Pharmacol. 119:143-152; 1985.
61. Kennett, G. A.; Dickinson, S. L.; Curzon, G. Enhancement of some 5-HT-dependent behavioral responses following repeated immobilization in rats. Brain Res. 330:253-263; 1985.
62. 1A agonists and conventional antidepressants in an animal model of depression. Eur. J. Pharmacol. 134:265-274; 1987.
63. Korte, S. M.; Bouws, G. A. H.; Bohus, B. Adrenal hormones in rats before and after stress-experience effects of ipsapirone. Physiol. Behav. 51:1129-1133; 1992.
64. Kuroda, Y.; Mikuni, M.; Nomura, N.; Takahashi, K. Differential effect of subchronic dexamethasone treatment on serotonin-2 and beta-adrenergic receptors in rat cerebral cortex and hippocampus. Neurosci. Lett. 155:195-198; 1993.
65. López, L. F.; Chalmers, D. T.; Vázquez, D. M.; Akil, H.; Watson, S. L. Chronic unpredictable stress downregulates serotonin-1A receptor in the hippocampus. Soc. Neurosci. Abstr. 19: 216; 1993.
66. Maier, S. F.; Kalman, B. A.; Grahn, R. E. Chlordiazepoxide microinjected into the region of the dorsal raphe nucleus eliminates the interference with escape responding produced by inescapable shock whether administered before inescapable shock or escape testing. Behav. Neurosci. 108:121-130; 1994.
67. Maier, S. F.; Grahn, R. E.; Kalman, B. A.; Sutton, L. C.; Wiertelak, E. P.; Watkins, L. R. The role of the amygdala and dorsal raphe nucleus in mediating the behavioral consequences of inescapable shock. Behav. Neurosci. 107:377-388; 1993.
68. Mamounas, L. A.; Mullen, C. A.; O'Hearn, E.; Molliver, M. E. Dual serotonergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J. Comp. Neurol. 314:558-586; 1991.
69. Maru, E.; Takahashi, L. K.; Iwahara, S. Effects of median raphe nucleus lesions on hippocampal EEG in the freely moving rat. Brain Res. 163:223-234; 1979.
70. McBlane, J. W.; Handley, S. L. Effects of two stressors on behavior in the elevated X-maze: Preliminary investigation of their interaction with 8-OH-DPAT. Psychopharmacology (Berlin) 116:173-182; 1994.
71. McEwen, B.; Gould, E. A.; Sakai, R. R. The vulnerability of the hippocampus to protective and destructive effects of glucorticoids in relation to stress. Br. J. Psychiatry 160(Suppl. 15):18-24; 1992.
72. McKittrick, C. R.; Blanchard, D. C.; Blanchard, R. J.; McEwen, B. S.; Sakai, R. R. Serotonin receptor binding in a colony model of chronic stress. Biol. Psychiatry 37:383-393; 1995.
73. McNair, D. M.; Frankenthaler, L. M.; Czerlinsky, T.; White, T. W.; Sasson, S.; Fischer, S. Simulated public speaking as a model of clinical anxiety. Psychopharmacology (Berlin) 77:7-10; 1982.
74. McNaughton, M. E.; Patterson, T. L.; Irwin, M. R.; Grant, I. The relationship of life adversity, social support, and coping to hospitalization with major depression. J. Nerv. Mental Dis. 180: 491-497; 1992.
75. McTavish, D.; Heel, R. C. Dexfenfluramine: A review of its pharmacological properties and therapeutic potential in obesity. Drugs 43:713-733; 1992.
76. 1B receptors in the dorsal hippocampus and cortex of rats. Neuroendocrinology 55:444-450; 1992.
77. 1A receptors on elevated plus maze exploration after single restraint experience. Behav. Brain Res. (in press).
78. Montgomery, K. C. The relationship between fear induced by novel stimulation and exploratory behaviour. J. Comp. Physiol. Psychol. 48:254-260; 1955.
79. Morgan, J. T.; Curran. T. Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogene fos and jun. Annu. Rev. Neurosci. 14:421-451; 1991.
80. Nausieda, P. A.; Carve, P. M.; Weiner, W. J. Modification of central serotonergic and dopaminergic behaviours in the course of chronic corticosteroid administration. Eur. J. Pharmacol. 78: 335-343; 1982.
81. Nemeroff, C. B.; Krishnan, K. R. R.; Reed, D.; Leder, R.; Beam, C.; Dunnick, R. Adrenal gland enlargement in major depression. Arch. Gen. Psychiatry 49:384-387; 1992.
82. Nutt, D. J. Anxiety and its therapy: Today and tomorrow. In: Briley, M.; File, S. E., eds. New concepts in anxiety. London: Macmillan Press; 1991:1-12.
83. O'Connor, J. J.; Rowan, M. J.; Anwyl, R. Serotoninergic depression of auditory evoked responses recorded in the rat hippocampus: Effect of repeated buspirone treatment. Brain Res. 573: 190-196; 1992.
84. Odwyer, A. M.; Lightman, S. L.; Marks, M. N.; Checkley, S. A. Treatment of major depression with metyrapone and hydrocortisone. J. Affect. Dis. 33:123-128; 1995.
85. 1A receptor agonist, in the rat. Eur. J. Pharmacol. 234:29-34; 1993.
86. Padovan, C. M.; Guimar&atiles;es, F. S. Attenuation of behavioural consequences of immobilization stress by intra-hippocampal microinjection of zimelidine. Braz. J. Med. Biol. Res. 26: 1085-1089; 1993.
87. Papp, M.; Klimek, V.; Willner, P. Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression. Psychopharmacology (Berlin) 114: 309-314; 1994.
88. Paykel, E. S. Psychosocial influences on the curse of depression. In: Swinkels, J. A.; Blijleven, W., eds. Depression, anxiety and aggression: Factors that influence the course. Houten: Medidact; 1988:55-62.
89. Peeters, B. W. M. M.; Broekkamp, C. L. E. Involvement of corticosteroids in the processing of stressful life-events. A possible implication for the development of depression. J. Steroid. Biochem. Mol. Biol. 49:417-427; 1994.
90. Peeters, B. W. M. M.; Smets, R. J. M.; Broekkamp, C. L. E. The involvement of glucocorticoids in acquired immobility response is dependent on the water temperature. Physiol. Behav. 51:127-129; 1992.
91. Pellow, S.; Chopin, P.; File, S. E.; Briley, M. Validation of open : closed arm entries in the elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14:149-167; 1985.
92. Petersen, E. N.; Scheel-Krüger, J. Anticonflict effects of 5-HT antagonists by intraamygdaloid injection. Abstr. of the 14th CINP Cong.; 1984:654.
93. 1 receptors in different brain structures of rats with isolation syndrome. Gen. Pharmacol. 21:223-225; 1990.
94. 1A receptor in slices of the rat hippocampal dentate gyrus. Brain Res. 613:326-330; 1993.
95. Sandi, C.; Rose, S. P. R. Corticosterone enhances long-term retention in one-day-old chicks trained in a weak passive avoidance learning paradigm. Brain Res. 647:106-112; 1994.
96. Series, H. G.; Cowen, P. J.; Sharp, T. p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology (Berlin) 116:508-514; 1994.
97. Shapira, B.; Cohen, J.; Newman, N. E.; Lerer, B. Prolactin response to fenfluramine and placebo. Challenge following maintenance pharmacotherapy withdrawal in remitted depressed. Biol. Psychiatry 33:531-535; 1993.
98. 1A agonists and L-5-HTP in Montgomery's conflict test. Pharmacol. Biochem. Behav. 32:259-265; 1989.
99. Solyom, L. Controlling panic attacks with fenfluramine. Am. J. Psychiatry 151:621-622; 1994.
100. Targum, S. D.; Marshall, L. E. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res. 28:295-306; 1989.
101. Thakore, J. H.; Dinan, T. G. Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression. Biol. Psychiatry 37:364-368; 1995.
102. Thiébot, M. H.; Jobert, A.; Soubrié, P. Chlordiazepoxide and GABA injected into the raphe dorsalis release the conditioned behavioural suppression induced in rats by a conflict procedure without nociceptive component. Neuropharmacology 19:633-641; 1980.
103. Titze de Almeida, R.; Shida, H.; Guimarães, F. S.; Del Bel, E. A. Stress-induced expression of the c-fos proto-oncogene in the hippocampal formation. Braz. J. Med. Biol. Res. 27:1083-1088; 1994.
104. 3H]ketanserin binding sites during immobilization stress in the rat frontal cortex. Brain Res. 527: 198-203;1990.
105. Treit, D.; Menard, J.; Royan, C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:463-469; 1993.
106. Tye, N. C.; Everitt, B. J.; Iversen, S. D. 5-Hydroxytryptamine and punishment. Nature 268:741-742; 1977.
107. Viana, M. B.; Silveira, R.; Graeff, F. G. D-Fenfluramine releases 5-HT from terminals of the dorsal raphe nucleus. Braz. J. Med. Biol. Res. (in press).
108. Viana, M. B.; Tomaz, C.; Graeff, F. G. The elevated T-maze: A new animal model of anxiety and memory. Pharmacol. Biochem. Behav. 49:549-554; 1994.
109. Villani, F.; Johnston, D. Serotonin inhibits induction of long-term potentiation at commissural synapses in hippocampus. Brain Res. 606:304-308; 1993.
110. Willner, P. Animal models of depression: An overview. Pharmacol. Ther. 45:425-455; 1990.
111. Wise, C. D.; Berger, B. D.; Stein, L. Benzodiazepines: Anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 177:180-183; 1972.
112. Wooley, C. S.; Gould, E.; McEwen, B. S. Exposure to excess glucocorticoids alters dendrite morphology of adult hippocampal pyramidal neurons. Brain Res. 531:225-231; 1990.